Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.55 |
| ▸ | PNP | P00491 | 3/20 | 0.51 |
| ▸ | TK1 | P04183 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19569930 | 0.86 | XDH (0.55) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL48090 | 0.83 | XDH (0.51) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL21137720 | 0.83 | XDH (0.52) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL25808580 | 0.83 | HPGD (0.43) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL22399377 | 0.83 | XDH (0.38) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL986800 | 0.80 | XDH (0.60) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL29138701 | 0.79 | XDH (0.48) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL41787 | 0.78 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL15005119 | 0.78 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL27667185 | 0.78 | XDH (0.63) | XDHPNPTK1BLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | XDH 1435/4885PNP 174/4885TK1 216/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | XDH 592/4885PNP 138/4885TK1 240/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | XDH 592/4885PNP 138/4885TK1 240/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | XDH 592/4885PNP 138/4885TK1 240/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | XDH 16/4885PNP 302/4885TK1 323/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | XDH 2898/4885PNP 1202/4885TK1 326/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | XDH 1748/4885PNP 348/4885TK1 55/4885 |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | XDH 2898/4885PNP 1202/4885TK1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.